deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01131364

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

A Dose-finding, Pharmacokinetic, Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Sponsor: Philogen S.p.A.

Conditions Advanced Solid Tumor Breast Cancer
Interventions F16IL2 in combination with doxorubicin
Last updated: Feb 24, 2014 Started: Jun 30, 2008 Primary completion: Mar 31, 2012 Completion: Dec 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Philogen S.p.A.

More terminations from Philogen S.p.A.

Other Advanced Solid Tumor trials with similar outcome

Browse all Advanced Solid Tumor trials

A PHASE1/PHASE2 clinical study on Advanced Solid Tumor and Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Philogen S.p.A. and has accumulated 0 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

No change history available.

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Philogen S.p.A.
Data source: Philogen S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations